Artículos por temáticas

Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease.

Zhu J, Shen B, Lu L, Lan W, Pan Y, Zhang L, Dong J, Wang M, Zhang L.

J Neurol Sci. 2017 Jan 15;372:471-476. doi: 10.1016/j.jns.2016.10.043.

Modulations on cortical oscillations by subthalamic deep brain stimulation in patients with Parkinson disease: A MEG study.

Cao CY, Zeng K, Li DY, Zhan SK, Li XL, Sun BM.

Neurosci Lett. 2017 Jan 1;636:95-100. doi: 10.1016/j.neulet.2016.11.009.

Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population.

Giri A, Mok KY, Jansen I, Sharma M, Tesson C, Mangone G, Lesage S, Bras JM, Shulman JM, Sheerin UM; International Parkinson's Disease Consortium (IPDGC)., Díez-Fairen M, Pastor P, Martí MJ, Ezquerra M

Neurobiol Aging. 2017 Feb;50:167.e11-167.e13. doi: 10.1016/j.neurobiolaging.2016.10.004.

Association of the DRD2 CA(n)-STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists.

Xu S, Liu J, Yang X, Qian Y, Xiao Q.

J Neurol Sci. 2017 Jan 15;372:433-438. doi: 10.1016/j.jns.2016.08.005.

Gait initiation is impaired in subjects with Parkinson's disease in the OFF state: Evidence from the analysis of the anticipatory postural adjustments through wearable inertial sensors.

Bonora G, Mancini M, Carpinella I, Chiari L, Horak FB, Ferrarin M.

Gait Posture. 2017 Jan;51:218-221. doi: 10.1016/j.gaitpost.2016.10.017.

Neuroprotective effects of endurance exercise against neuroinflammation in MPTP-induced Parkinson's disease mice.

Jang Y, Koo JH, Kwon I, Kang EB, Um HS, Soya H, Lee Y, Cho JY.

Brain Res. 2017 Jan 15;1655:186-193. doi: 10.1016/j.brainres.2016.10.029.

TMEM230 mutation analysis in Parkinson's disease in a Chinese population.

Yan W, Tang B, Zhou X, Lei L, Li K, Sun Q, Xu Q, Yan X, Guo J, Liu Z.

Neurobiol Aging. 2017 Jan;49:219.e1-219.e3. doi: 10.1016/j.neurobiolaging.2016.10.007.

Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.

Wang L, Heckman MG, Aasly JO, Annesi G, Bozi M, Chung SJ, Clarke C, Crosiers D, Eckstein G, Garraux G, Hadjigeorgiou GM, Hattori N, Jeon B, Kim YJ, Kubo M, Lesage S, Lin JJ, Lynch T, Lichtner P, Melli

Neurobiol Aging. 2017 Jan;49:217.e1-217.e4. doi: 10.1016/j.neurobiolaging.2016.09.022.

Mutation analysis of CHCHD2 gene in Chinese Han familial essential tremor patients and familial Parkinson's disease patients.

Gao C, Chen YM, Sun Q, He YC, Huang P, Wang T, Li DH, Liang L, Liu J, Xiao Q, Chen SD.

Neurobiol Aging. 2017 Jan;49:218.e9-218.e11. doi: 10.1016/j.neurobiolaging.2016.10.001.

SMPD1 variants in Chinese Han patients with sporadic Parkinson's disease.

Mao CY, Yang J, Wang H, Zhang SY, Yang ZH, Luo HY, Li F, Shi M, Liu YT, Zhuang ZP, Du P, Wang YH, Shi CH, Xu YM.

Parkinsonism Relat Disord. 2017 Jan;34:59-61. doi: 10.1016/j.parkreldis.2016.10.014.

Treatment of Parkinson's disease in rats by Nrf2 transfection using MRI-guided focused ultrasound delivery of nanomicrobubbles.

Long L, Cai X, Guo R, Wang P, Wu L, Yin T, Liao S, Lu Z.

Biochem Biophys Res Commun. 2017 Jan 1;482(1):75-80. doi: 10.1016/j.bbrc.2016.10.141.

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.

Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, Riquelme E, González H, Vásquez M, Franco R, Pacheco R.

Neuropharmacology. 2017 Feb;113(Pt A):110-123. doi: 10.1016/j.neuropharm.2016.09.028.

Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism.

Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Kozio

Brain. 2017 Jan;140(Pt 1):98-117. doi: 10.1093/brain/aww261.

Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.

Bhattacharjee S, Talbot JG, Vijayashankar P.

Parkinsonism Relat Disord. 2017 Jan;34:69-70. doi: 10.1016/j.parkreldis.2016.10.021. No abstract available.

Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.

Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL.

Eur J Clin Pharmacol. 2017 Jan;73(1):99-103. doi: 10.1007/s00228-016-2142-x.